Last edition
News about "Merck KGaA "
Skyhawk Therapeutics has entered a strategic research collaboration worth over USD 2 billion with Merck KGaA, Darmstadt, Germany to develop novel RNA-targeting small molecules for neurological disorders.
Merck KGaA | 19/08/2025 | By Mrinmoy Dey
Merck KGaA Adopts Quris-AI's Bio-AI Platform for its Drug Development Pipeline
Quris-AI’s drug safety prediction platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug- induced toxicities better.
Merck KGaA | 09/01/2025 | By Aishwarya | 297
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy